Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 along with government funding notices; these changes update site metadata rather than the study details.SummaryDifference0.3%

- Check39 days agoChange DetectedNew version entries in the record history show updated study and recruitment statuses for NCT03976362.SummaryDifference0.0%

- Check53 days agoChange DetectedMinor updates: added a new date (2025-10-16) and a study status line (IPDSharing) for 2025-10-07, while removing an older date (2025-01-16).SummaryDifference0.7%

- Check68 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference7%

- Check75 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.2%

- Check90 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2 and removed the Back to Top control. These changes are minor and do not affect core content, pricing, stock, or time slots.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.